NPPA mandates strict monitoring of revised prices for 137 anti-cancer drugs, capping trade margins at 30%. Non-compliance faces penal action. Key PointsNPPA directs strict monitoring of revised prices for 137 non-scheduled anti-cancer drugs.The revised prices, effective November 9, cap the trade margin at 30% for these medicines.State Drug Controllers are instructed to ensure compliance and submit action taken reports.All manufacturers, stockists, and retailers must display updated price lists.